Background: Chondrosarcoma is one of the most common malignant bone tumors in adults. Conventional chondrosarcoma represents around 85% of all chondrosarcomas and is notoriously difficult to treat with chemotherapy.
Case Presentation: We describe a 67-year-old man with metastatic conventional chondrosarcoma who was treated with nivolumab. Treatment was discontinued after restaging showed increased tumor burden, which later proved to be pseudoprogression. The patient restarted nivolumab and continues to have a near complete response.
Conclusion: Conventional chondrosarcoma may be sensitive to checkpoint inhibitors. Further, this case demonstrates clearly the phenomenon of pseudo-progression in this disease, a factor that must be considered in the design of clinical trials and clinical care. This case supports additional study of immunomodulatory agents in this deadly disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156853 | PMC |
| http://dx.doi.org/10.1186/s40425-018-0413-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study Design: Systematic review.
Objectives: The objective of this review paper was to summarize targeted molecular therapy options for spinal chordoma and chondrosarcoma, and to provide an update on the relevant clinical trials open for recruitment.
Methods: A systematic review of the current literature was performed, according to PRISMA guidelines, to summarize the latest developments in non-surgical molecular treatment options for low grade malignant primary spinal tumours.
A promising role of noble metal NPs@MOFs in chondrosarcoma management.
Nanoscale
December 2024
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu 610041, China.
Chondrosarcoma, a challenging and malignant neoplasm originating from cartilage cells, poses significant diagnostic and therapeutic hurdles due to its resistance to conventional treatments and the complexity of its diagnosis. Noble metal nanoparticle-embedded metal-organic frameworks (NPs@MOFs) stand out as a novel approach for the diagnosis and treatment of chondrosarcoma. This review delves into the properties and applications of NPs@MOFs, focusing on their classification by noble metal type and their role in enhancing photothermal therapy (PTT), photodynamic therapy (PDT), targeted drug delivery and chondrosarcoma diagnosis.
View Article and Find Full Text PDFA rare case of dedifferentiated intracranial solitary fibrous tumor with chondrosarcomatous differentiation.
Neuropathology
December 2024
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
This report details a rare case of a 30-year-old female presenting with neurological symptoms, including headaches, seizures, and left-sided weakness. Imaging revealed a mass in the right parafalcine region of her brain. Surgical resection identified a tumor with two distinct components.
View Article and Find Full Text PDFHigh-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.
Int J Mol Sci
December 2024
Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
The term chondrosarcoma refers to a rare and heterogeneous group of malignant cartilaginous tumors that are typically resistant to chemotherapy and radiotherapy. Metastatic chondrosarcoma has a poor prognosis, and effective systemic therapies are lacking. Isocitrate dehydrogenase (IDH) mutations represent a potential therapeutic target, but IDH inhibitors alone have shown limited clinical efficacy to date.
View Article and Find Full Text PDFRare malignant primary spinal chondrosarcoma: A case report.
Radiol Case Rep
February 2025
Department of Pathology Anatomy, Faculty of Medicine PADJADJARAN University. Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia.
Article Synopsis
- Chondrosarcomas are malignant tumors that produce cartilage and are divided into primary and secondary types; primary chondrosarcomas are the third most common primary malignant bone tumors, accounting for 20%-27% of cases.
- A case study involving a 36-year-old man revealed a rare primary spinal chondrosarcoma with symptoms of back swelling and pain over 3 years, confirmed through imaging that showed a lytic sclerotic lesion and extensive infiltration.
- Diagnosis relies on imaging techniques like X-rays, CT, and MRI, and treatment typically involves en bloc resection and possibly high-dose radiotherapy to improve outcomes and monitor for recurrence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!